Contains Proteins Or Derivative Or Polysaccharides Or Derivative Patents (Class 424/499)
  • Patent number: 11065238
    Abstract: The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: July 20, 2021
    Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS), ÉCOLE PRATIQUE DES HAUTES ÉTUDES
    Inventors: Frédéric Darios, Giovanni Stevanin, Fanny Mochel, Julien Branchu, Maxime Boutry
  • Patent number: 11045464
    Abstract: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: June 29, 2021
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Patent number: 11045492
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 29, 2021
    Assignee: onCour Pharma, Inc.
    Inventor: John Puisis
  • Patent number: 11033602
    Abstract: Disclosed herein is a pulmonary administration device, comprising a spray nozzle unit and a cartridge containing an aqueous solution comprising from 70 to 400 mg A/m L of a sulfomethylated polymyxin, and use of sulfomethylated polymyxin in a device for pulmonary administration in a patient in need thereof.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: June 15, 2021
    Assignee: XELLIA PHARMACEUTICALS APS
    Inventor: Nenad Bencic
  • Patent number: 11013736
    Abstract: The invention discloses an oral solid preparation containing any one, or a mixture of two or more of crystalline form I, II, III, and IV of the compound represented by formula (A). The oral solid preparation of the present invention disintegrates rapidly, increasing dissolution rate thereof, thereby improving bioavailability. In particular, it is possible to solve the problem that an active material (active ingredient), which is high hygroscopic and becomes sticky after moisture absorption, can not be effectively disintegrated by conventional disintegrants. The present invention further relates to a use of the oral solid preparation in preparing an angiotensin II receptor antagonist or a use thereof in preparing medicine for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: May 25, 2021
    Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventors: Lei Liang, Yongkai Chen, Liu Hu, Wei Feng, Chaodong Wang
  • Patent number: 11007279
    Abstract: A major challenge in non-viral gene delivery remains finding a safe and effective delivery system. Colloidally stable non-viral gene vector delivery systems capable of overcoming various biological barriers, are disclosed. The gene vectors are biodegradable, non-toxic and highly tailorable for use in specific applications. The vectors include a mixture of biodegradable copolymers, such as PBAE, and biodegradable polymers conjugated with hydrophilic, neutrally charged polymer, such as PEG. The gene vectors demonstrate broad vector distribution and high transgene delivery in vivo, providing an efficient non-viral gene delivery system for localized therapeutic gene transfer. Methods of using the vectors to overcome biological barriers including mucus gel and extracellular matrix are provided. Methods of formulating the vectors are also provided.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: May 18, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Justin Hanes, Jung Soo Suk, Panagiotis Mastorakos
  • Patent number: 10993911
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 4, 2021
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10993912
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: May 4, 2021
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10912848
    Abstract: The present invention provides a dual-purpose photoacoustic tomography (PAT)/ultrasound contrast agent comprising: (a) a micro-bubble containing gas and porphyrin therein; and (b) nanoparticles bound on a surface of the micro-bubble and containing a drug. The contrast agent of the present invention can be used in both the ultrasound diagnosis and the photoacoustic image diagnosis, and can significantly increase the accuracy of photoacoustic images.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: February 9, 2021
    Assignee: IMGT CO, LTD.
    Inventors: Hyun Cheol Kim, Hyung Won Moon, Jin Ho Chang
  • Patent number: 10786486
    Abstract: Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: September 29, 2020
    Inventor: Vasilios Voudouris
  • Patent number: 10772833
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: September 15, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10773231
    Abstract: This invention relates to a process for colloidosome-type microcapsules elaboration from solid particles microcapsules obtained by ionic gelation. In the process, an (O/W) type emulsion is initially generated stabilized with the solid particles microcapsules, and then the particles are fixed to the interface by adsorption of polyelectrolytes, cross-linking, heat treatment or fatty coating, generating the colloidosome with the water-insoluble phase encapsulated in the core and covered by the shell particles.
    Type: Grant
    Filed: June 18, 2016
    Date of Patent: September 15, 2020
    Assignees: Nexentia S.A.S., Universidad de Antioquia
    Inventors: Herley Casanova, César Augusto Pérez Zapata
  • Patent number: 10765741
    Abstract: This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., Abraxane®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: September 8, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10751293
    Abstract: A multilayered polymer composite film includes a water-soluble polymer matrix and a plurality of fibers embedded within the water soluble polymer matrix. The fibers include a water insoluble polymer material and at least one of a non-polymeric hydrophobic therapeutic agent or a non-polymeric hydrophobic cosmetic agent incorporated in the water insoluble polymer material. The fibers have a rectangular cross-section, and extend the entire length of the multilayered polymer composite film.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: August 25, 2020
    Assignee: Case Western Reserve University
    Inventors: Eric Baer, Gary E. Wnek, Mohammad Mofidfar, Jia Wang
  • Patent number: 10711040
    Abstract: The present invention relates to novel low substituted polymyxins and compositions thereof.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: July 14, 2020
    Assignee: XELLIA PHARMACEUTICALS APS
    Inventors: Vidar Bjornstad, Solvi Gunnes, Torben Koch, Claes Melander
  • Patent number: 10617648
    Abstract: The present invention provides for method of improving flowability and loose bulk density of functionalized natural- and/or synthetic calcium carbonate comprising material, to the use of such improved material in ready to use granules and thereof produced dispersible dosage forms.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 14, 2020
    Assignee: Omya International AG
    Inventors: Leonie Wagner-Hattler, Maxim Puchkov, Jörg Huwyler, Tanja Stirnimann, Carolina Diaz Quijano, Joachim Schoelkopf, Patrick A. C. Gane, Daniel E. Gerard
  • Patent number: 10611908
    Abstract: Biocompatible block copolymer micelles for use in mucoadhesive drug delivery are provided. The micelles comprise a degradable hydrophobic polymer, a degradable synthetic hydrophilic polymer and a mucoadhesive polymer. The micelles are particularly useful for ophthalmic uses.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: April 7, 2020
    Assignee: McMaster University
    Inventors: Heather Sheardown, Graeme Prosperiporta, Stephanie Kedzior, Benjamin Muirhead
  • Patent number: 10568992
    Abstract: The present invention relates to the production of endothelialized matrices and materials from immature endothelial cells using substrates to which particular peptides have been grafted. The resultant substrates can be used to capture and support immature endothelial cells. Further, the methods and compositions of the present invention provide viable cell delivery platforms that allow for production and provision of endothelialized medical devices and implants, including vascular grafts, stents, shunts, and valves, endothelialized surfaces and channels for in vitro testing devices, including microfluidic chips, and materials that support vascularization such as for use in engineered tissues. The present invention includes novel methods required for the successful production of cellularized substrates, systems and components used for the same, and methods of using the resultant cell and tissue compositions.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: February 25, 2020
    Assignee: Auburn University
    Inventors: Elizabeth A. Lipke, Wen Jun Seeto
  • Patent number: 10561161
    Abstract: Comestible products, for example beverage products, are disclosed containing encapsulated probiotic bacteria having resistance to subjection to at least thermal and acidic conditions. Beverage products include at least one aqueous liquid and capsules comprising a gelled mixture of alginate and denatured protein, and probiotic bacteria entrapped within the gelled mixture. The average particle size of the capsules is optionally less than 1000 microns (?m) in diameter, such as less than 500 ?m in diameter. Methods are provided for making such encapsulated probiotics by providing a mixture comprising sodium alginate, denatured protein and active probiotic cells, and combining the mixture with a divalent cation to initiate cold gelation of the sodium alginate and denatured protein to form a second mixture. The second mixture is passed through an opening having a diameter of less than 1000 ?m to form capsules. The weight ratio of protein to alginate is from 1:1 to 9:1.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: February 18, 2020
    Assignees: Pepsico, Inc., Massey University
    Inventors: Yuan Fang, Breda Kennedy, Teodoro Rivera, Kyoung-Sik Han, Anil Kumar Anal, Harjinder Singh
  • Patent number: 10537131
    Abstract: Electrically heated cigarettes used in an electrical smoking system include a flavoring-release additive and sorbent effective to remove one or more gas-phase constituents of mainstream tobacco smoke. The flavoring-release additive includes gamma cyclodextrin and at least one flavoring. Flavoring is released in a cigarette upon the flavoring-release additive reaching at least a minimum temperature during smoking. The flavoring-release additive can have various forms including, for example, powder and films.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: January 21, 2020
    Assignee: Philip Morris USA Inc.
    Inventors: Munmaya K. Mishra, Susan E. Wrenn, Jay A Fournier
  • Patent number: 10370434
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: August 6, 2019
    Assignee: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON
    Inventors: Laura Soucek, Marie-Eve Beaulieu
  • Patent number: 10364283
    Abstract: The present invention relates to a collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from peptides of which at least 50% by weight, in particular at least 70% by weight have a molecular weight of 1,500 Da to 3,500 Da, and which have a mean molecular weight in the range from 4,000 Da to 8,000 Da, in particular in the range from 4,500 Da to 6,000 Da. The invention also relates to the use of this collagen hydrolysate as an active ingredient to maintain and/or improve the health of the bones, in particular to prevent and/or treat osteoporosis. The invention further relates to a nutritional supplement which comprises the collagen hydrolysate.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: July 30, 2019
    Assignee: GELITA AG
    Inventors: Steffen Oesser, Monika Giesen-Wiese, Hans-Ulrich Frech, Stephan Hausmanns
  • Patent number: 10328155
    Abstract: The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-?B-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: June 25, 2019
    Assignee: NANOCARE TECHNOLOGIES, INC.
    Inventor: Jose E. Fehr Pereira Lopes
  • Patent number: 10300016
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 28, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10292909
    Abstract: The disclosure provides biocompatible dental material that is moldable and biodegradable and provides sustained and/or controlled delivery of one or more local anesthetics within a dental cavity or space. Such dental material is customizable for the size and shape needed for a particular patient or particular application. The dental material may also provide customizable sustained and/or controlled delivery of one or more local anesthetics.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: May 21, 2019
    Assignees: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, RESEARCH TRIANGLE INSTITUTE
    Inventors: Leah Marie Johnson, Ginger Denison Rothrock, Sarah Dorothy Shepherd, Sandra Cordel O'Buckley, Andrea Gail Neely
  • Patent number: 10232046
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 19, 2019
    Assignee: Baxter International Inc.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Patent number: 10208308
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flue infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and prevention orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 19, 2019
    Assignee: Socpra Sciences Sante Et Humaines S.E.C.
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Patent number: 10207252
    Abstract: The present disclosure relates to the use of pristine and surface functionalized cellulose nanocrystal (CNC) incorporated hydrogel beads as adsorbent materials for water treatment applications. Here the hydrogel beads were prepared by ionic crosslinking of biopolymer sodium alginate using calcium chloride.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: February 19, 2019
    Inventors: Nishil Mohammed, Nathan Grishkewich, Kam Chiu Tam, Richard Berry
  • Patent number: 10182996
    Abstract: Described herein are polymeric nanoparticles that include a therapeutic agent, and methods of making and using such therapeutic nanoparticles. In some embodiments, the contemplated nanoparticles may include an excipient.
    Type: Grant
    Filed: July 5, 2015
    Date of Patent: January 22, 2019
    Assignee: Pfizer Inc.
    Inventor: Hong Wang
  • Patent number: 10172947
    Abstract: A composition including hydrophobized chitosan can be used as an antiparasitic and/or antifungal agent or in the treatment of parasitic and/or fungal infections. The composition may include an antifungal agent and hydrophobized chitosan. The antifungal agent can be in association with the hydrophobized chitosan, with the latter being more preferably in the particle form, or the antifungal agent can be encapsulated in particles including the hydrophobized chitosan. The use of the composition as an antifungal agent or in the treatment of fungal infections, and a method for manufacturing the composition are also described.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: January 8, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIFQUE (CNRS), UNIVERSITE PARIS-SUD 11
    Inventors: Kawthar Bouchemal, Christian Bories, Philippe Loiseau, Christine Vauthier-Holtzscherer, Sebastien Pomel, Benedicte Pradines
  • Patent number: 10124068
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 13, 2018
    Assignee: Baxter International, Inc.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Patent number: 10092660
    Abstract: The invention relates to solid compositions that may be suitable for administering a therapeutic agent to a subject. The invention also relates to methods of making such solid compositions. The invention further relates to methods of treating a disease, condition, or disorder by administering to a subject such solid compositions.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: October 9, 2018
    Assignee: STC.UNM
    Inventors: Hugh Smyth, Ibrahim M. El-Sherbiny
  • Patent number: 10047128
    Abstract: The present invention is a peptide lock that comprises at least one peptide that is genetically encoded into the Adeno-associated virus (AAV) capsid that block biologically active domains on the virus capsid surface. The peptide lock, can be processed by biological enzymes to restore biological behavior of the capsid-displayed domains, thus ‘decoding the lock’ or opening the lock. A method of forming the peptide lock comprises providing at least one peptide, providing an Adeno-associated virus capsid and genetically inserting the at least one peptide into the Adeno-associated virus capsid to block the biologically active domains on the virus capsid surface.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: August 14, 2018
    Assignee: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Justin Judd, Junghae Suh, Jonathan Silberg
  • Patent number: 10022410
    Abstract: The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to an extract of a plant-based “Traditional Chinese Medicinal” product and devices incorporating such agents for the delivery thereof to bleeding wounds.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: July 17, 2018
    Assignee: Ethicon, Inc.
    Inventors: Yi-Lan Wang, Xintian Ming
  • Patent number: 9987221
    Abstract: In accordance with one aspect of the invention, injectable compositions are provided, which contain temperature-sensitive hydrogel particles. The hydrogel particles may be provided in dry form, or they may be provided in hydrated form in an aqueous fluid. The temperature-sensitive hydrogel particles may have an upper critical solution temperature (UCST) below normal body temperature, they may have a lower critical solution temperature (LCST) above normal body temperature, or they may have a LCST that changes from below normal body temperature to above normal body temperature after injection into a subject.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: June 5, 2018
    Assignee: Boston Scientific Scimed, Inc.
    Inventor: Robert E. Richard
  • Patent number: 9980914
    Abstract: A pharmaceutical product comprising lyophilized polymer matrix including a biologically active compound, of particular utility for embolization, having improved rehydration properties is packaged in an airtight package under vacuum.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 29, 2018
    Assignee: BIOCOMPATIBLES UK LIMITED
    Inventors: Sean Willis, Rosemary Palmer
  • Patent number: 9980977
    Abstract: The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: May 29, 2018
    Assignee: Carbylan Therapeutics, Inc.
    Inventors: David M. Gravett, George Y. Daniloff, Pingren He
  • Patent number: 9968563
    Abstract: An object of the present invention is to provide a method for producing a microcapsule formulation using a biodegradable polymer, the method being capable of avoiding direct contact of a peptidic physiologically active substance with an organic solvent layer, and achieving a high encapsulation efficiency of the peptidic physiologically active substance.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: May 15, 2018
    Assignees: JGC CORPORATION, INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Yasuaki Ogawa, Naoki Tahara, Tomoya Yamashita, Shuzo Kojima, Felice Cheng, Sung-En Chen, Jui-Mei Lu
  • Patent number: 9962628
    Abstract: The invention relates to the use of a citrate solution for affinity-chromatographic removal of C-reactive protein (CRP) from biological fluids, wherein the CRP is affinity-chromatographically removed using (Ca2+-dependent) binding of CRP to a column material functionalized with ?-phosphonooxyalkyl ammonium groups and/or with ?-ammoniumalkoxy-hydroxy-phosphoryloxy groups.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: May 8, 2018
    Assignee: Pentracor GmbH
    Inventors: Ahmed Sheriff, Birgit Vogt, Stephan Mattecka
  • Patent number: 9943466
    Abstract: The disclosure provides biocompatible dental material that is moldable and biodegradable and provides sustained and/or controlled delivery of one or more local anesthetics within a dental cavity or space. Such dental material is customizable for the size and shape needed for a particular patient or particular application. The dental material may also provide customizable sustained and/or controlled delivery of one or more local anesthetics.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: April 17, 2018
    Assignees: Research Triangle Institute, The University of North Carolina at Chapel Hill
    Inventors: Leah Marie Johnson, Ginger Denison Rothrock, Sarah Dorothy Shepherd, Sandra Cordel O'Buckley, Andrea Gail Neely
  • Patent number: 9938382
    Abstract: The present invention aims to provide an industrially advantageous method of producing a powdery pseudopolyrotaxane with a high inclusion ratio. The present invention relates to a method for producing a pseudopolyrotaxane, including: an inclusion step of mixing a polyethylene glycol and a cyclodextrin in an aqueous medium to form an aqueous dispersion of pseudopolyrotaxane that contains pseudopolyrotaxane particles in which the polyethylene glycol is included in the cavities of the cyclodextrin molecules in a skewered manner; and a drying step of drying the aqueous dispersion of pseudopolyrotaxane produced in the inclusion step to obtain the pseudopolyrotaxane. In the drying step, the aqueous dispersion of pseudopolyrotaxane is sprayed and dried in a heated gas-stream.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: April 10, 2018
    Assignees: Sumitomo Seika Chemicals Co., Ltd., Advanced Softmaterials Inc.
    Inventors: Tomoaki Yamasaki, Shinya Okazaki, Hiroki Okazaki, Shigeki Hamamoto, Changming Zhao
  • Patent number: 9925301
    Abstract: Provided herein relates to methods for preparing micron range silk fibers (or silk microfibers) and compositions comprising a micron range silk fiber (or a silk microfiber). The micron range silk fibers (or silk microfibers) can be used in various applications ranging from fillers in cosmetics to reinforcement materials to design high strength composites, e.g., reinforced scaffolds. In some embodiments, the silk microfiber-reinforced scaffolds can be used for bone graft applications because of their high compressive strength.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: March 27, 2018
    Assignee: TRUSTEES OF TUFTS COLLEGE
    Inventors: David L. Kaplan, Biman B. Mandal
  • Patent number: 9918971
    Abstract: Aerosol formulations of granisetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: March 20, 2018
    Assignee: LUXENA PHARMACEUTICALS, INC.
    Inventors: George Lu, Xiaodong Li, Biao Lu
  • Patent number: 9913805
    Abstract: A nano- or micro-scale therapeutic agent is provided for use in the treatment of an infection of a human or animal. The agent includes micro- and/or nano-particle carriers loaded with at least one inert precursor chemical. The carriers encapsulate the precursor which after release from the carrier are activatable by the physiological milieu in situ at the site of the infection to form an antimicrobial agent. Preferably, the precursor chemical or chemicals form an oxidative biocide on release, which oxidative biocide is hydrogen peroxide. Advantageously, the precursor chemicals also include an acetyl donor that on release reacts with the hydrogen peroxide to produce a mixture of peracetic acid and hydrogen peroxide. The carrier is preferably in the form of micro- and/or nano-particles that have been manufactured using a thermally induced phase separation (TIPS) process, for example the carrier may be a biodegradable polymer such as poly(lactic-co-glycolic acid) (PLGA).
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: March 13, 2018
    Assignee: AGA NANOTECH LTD
    Inventor: Adrian Neville Fellows
  • Patent number: 9839617
    Abstract: Provided is a nanoparticle including a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: December 12, 2017
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Simon Benita, Taher Nassar, Liat Kochavi-Soudry
  • Patent number: 9788754
    Abstract: The present invention relates to a medical method of managing a cerebrovascular insult, the method comprising the following steps in this order: a) placing a patient on a patient support unit; b) positioning a mobile tomographic imaging system in a predetermined position relative to the patient support unit with the patient placed on the patient support unit; c) imaging at least part of the patient's brain using an imaging unit of the tomographic imaging system, the imaging comprising in particular generating an image describing the functioning of the patient's blood vessel system; d) determining, in dependence on the result of the imaging, whether the patient support unit should be rotated relative to the tomographic imaging system with the patient placed on the patient support unit so that the patient is free of the imaging unit in order to conduct a medical intervention on the patient's blood vessel system, or whether the patient support unit may remain in its position relative to the tomographic imagi
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: October 17, 2017
    Assignee: Brainlab AG
    Inventor: Stefan Vilsmeier
  • Patent number: 9789156
    Abstract: The treatment of human epidermal growth factor receptor 2-positive (HER2+) cancers using a combination of anti-mucin 1 (anti-MUC1) therapy and anti-human epidermal growth factor receptor 2 (anti-HER2) therapy is described, such as the treatment of trastuzamab-resistant cancers, both primary and acquired, using the same combination of agents.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 17, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • Patent number: 9789192
    Abstract: The present invention relates to a composition for oral use in the treatment of gastrointestinal pathologies comprising silicone antifoaming agents in an oily solvent medium, wherein the concentration of said silicone antifoaming agents is between 0.1% and 80% by weight.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: October 17, 2017
    Assignee: Gruppo Farmaimpresa S.r.l.
    Inventor: Daniele Scetta
  • Patent number: 9752149
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: September 5, 2017
    Assignee: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Patent number: 9730982
    Abstract: Described are implantable, malleable medical materials comprising mineral particles, insoluble collagen fibers, and a gel-forming polysaccharide component and/or another added gel-former. The malleable medical materials can be used treat bone or other tissue defects in patients, including in conjunction with biologically active factors such as osteogenic proteins. Also described are methods and materials that can be used to prepare the malleable medical materials.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 15, 2017
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: William F. McKay, Jeffrey L. Scifert, Kathy Remsen, Didier Billy, Mirian Gillissen, Scott M. Vickers